Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne contract development and manufacturing organization (CDMO) facility, effective June 14, 2026. The move comes as the company continues to expand its contract development and manufacturing platform, signaling strategic growth in its service offerings.
Elmalem, who has supported Scinai as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience. In his new role, he will oversee site operations and engineering activities at the Yavne facility. His leadership is expected to enhance operational efficiency and support the company’s efforts to scale its CDMO business.
The appointment underscores Scinai’s commitment to strengthening its manufacturing capabilities. The CDMO subsidiary, Scinai Biopharma Services, provides development and manufacturing services to biotechnology and pharmaceutical companies, and the expansion of this platform could have significant implications for the industry. By bolstering its leadership with an experienced operations executive, Scinai aims to better serve its clients and potentially capture a larger share of the growing CDMO market.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. It advances a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The company’s dual focus on internal drug development and external CDMO services positions it uniquely in the biotech landscape. The expansion of its CDMO operations could provide additional revenue streams and support its drug development programs.
For investors, the appointment of a seasoned operations head may signal that Scinai is prioritizing execution and scalability. The company’s ability to attract experienced talent like Elmalem could be viewed as a positive indicator of its growth trajectory. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
Full details of the press release can be found at https://ibn.fm/VLt3w.
